Market Overview

PEGylated Drugs Market in Europe and North America will achieve 5% CAGR to bypass $10.5 Billion by 2024

Share:

PEGylated Drugs Market in Europe and North America will achieve 5% CAGR to bypass $10.5 Billion by 2024

U.S. PEGylated drugs market revenue was at over USD 6 billion in 2017 and is expected to surpass USD 8 billion by 2024, helped by growing incidences of cancer along with rising mortality rates associated with chronic ailments in the country

PR Newswire

SELLBYVILLE, Del., August 15, 2018 /PRNewswire-iReach/ -- The North America & Europe PEGylated Drugs Market revenue is poised to beat USD 10.5 Billion by 2024; as per a new research report. by Global Market Insights, Inc. Growing biologics sector in the developed regions will substantially influence the PEGylated drugs industry over the coming few years. Growing investment for biologics, efficient regulatory process coupled with increased efforts of industry players to develop innovative medicines and drugs are factors contributing towards market growth.

Rising incidences of chronic ailments including cancer, multiple sclerosis in the developed economies will act as a major driver for PEGylated drugs market growth. Favourable government support along with increasing funding for research and development by major biopharmaceutical companies in the U.S. and Europe will propel industry growth.

Request for a sample of this research report @ https://www.gminsights.com/request-sample/detail/2511

Germany pegylated drugs market will experience considerable growth due to growing prevalence of chronic diseases along with presence of well-established and local players developing PEGylated drugs in the country.

U.S. was dominating the PEGylated drugs industry due to the presence of large patient pool suffering from chronic disorders along with growing biologics sector in the country. Increasing investments for R&D by pharmaceutical players along with availability of numerous approved pegylated drugs will further contribute towards market growth.

Some of the notable industry players are Shire Group, UCB, Merck, AstraZeneca, Amgen, Sigma Tau, Biogen, Pfizer and Roche. Growing focus of major industry players on research activities for the development of effective therapeutics along with the presence of considerable number of products in their pipeline will escalate market growth in the coming years.

Potential safety risks such as vacuolation and hypersensitivity reactions due to uptake of pegylated drugs will impede market growth. Drug recalls owing to adverse side effects of drugs is further expected to hamper revenue size.

Make an inquiry for purchasing this report @ https://www.gminsights.com/inquiry-before-buying/2511

Cancer dominated the industry owing to the high prevalence of the disease across North America and European region. Increasing government spending for cancer research along with availability of pegylated drugs such as Neulasta and Oncaspar offering numerous benefits for effective treatment of cancer will stimulate market growth in the future.

Multiple sclerosis will witness considerable growth over the coming years. This growth is attributable to increasing usage of Plegridy, a peginterferon beta-1 drug used for the treatment of relapsing multiple sclerosis.

Colony stimulating factors held the largest revenue share in 2017 due to increasing adoption of granulocyte CSF called pegfilgrastin. Benefits offered by such molecules such as reducing the risk of neutropenia and infections caused by bone marrow transplantation or chemotherapy will boost its market growth.

Browse key industry insights spread across 120 pages with 31 market data tables & 8 figures & charts from the report, "North America and Europe PEGylated Drugs Market" in detail along with the table of contents:

https://www.gminsights.com/industry-analysis/north-america-and-europe-pegylated-drugs-market

Sample Toc:

Chapter 2.  Executive Summary

2.1. North America & Europe PEGylated drugs industry 3600 synopsis, 2013 - 2024 (USD Million)

2.1.1.  Business trends

2.1.2.  Disease indication trends

2.1.3.  Type trends

2.1.4.  Regional trends

Chapter 3.  North America & Europe PEGylated Drugs Industry Insights

3.1. Industry segmentation

3.2. Industry impact forces

3.2.1.  Growth drivers

3.2.1.1.    Increasing prevalence of cancer in developed regions

3.2.1.2.    Rising R&D spending by biotechnology & pharmaceutical companies in U.S. and Europe

3.2.1.3.    Growing biologics sector in the developed economies

3.2.2.  Industry pitfalls & challenges

3.2.2.1.    Drug recalls in the U.S. & Europe

3.2.2.2.    Adverse drug reactions

3.3. Growth potential analysis

3.3.1.  By disease indication

3.3.2.  By type

3.4. Regulatory landscape

3.4.1.  U.S.

3.4.2.  Europe

3.5. Porter's analysis

3.6. Pipeline analysis

3.7. Competitive landscape, 2017

3.7.1.  Strategy dashboard

3.8. PESTEL analysis

Chapter 4.  North America & Europe PEGylated Drugs Market, By Disease Indication

4.1. North America & Europe PEGylated drugs market share by disease indication, 2017 & 2024 

4.2. Cancer

4.2.1.  Market estimates and forecast, by country, 2013 - 2024 (USD Million)

4.3. Hepatitis 

4.3.1.  Market estimates and forecast, by country, 2013 – 2024 (USD Million)

4.4. Multiple sclerosis

4.4.1.  Market estimates and forecast, by country, 2013 – 2024 (USD Million)

4.5. Gastrointestinal disorders

4.5.1.  Market estimates and forecast, by country, 2013 – 2024 (USD Million)

4.6. Others

4.6.1.  Market estimates and forecast, by country, 2013 – 2024 (USD Million)

Chapter 5.  North America & Europe PEGylated Drugs, By Type

5.1. North America & Europe PEGylated drugs market share by type, 2017 & 2024 

5.2. Monoclonal antibodies (mAbs)

5.2.1. Market estimates and forecast, by country, 2013 - 2024 (USD Million)

5.3. Colony stimulating factors

5.3.1.  Market estimates and forecast, by country, 2013 - 2024 (USD Million)

5.4. Interferons

5.4.1.  Market estimates and forecast, by country, 2013 - 2024 (USD Million)

5.5. Others

5.5.1.  Market estimates and forecast, by country, 2013 - 2024 (USD Million)

About Global Market Insights

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Media Contact: Jignesh Thakkar, Global Market Insights, Inc., +13028467766, sales@gminsights.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Global Market Insights

View Comments and Join the Discussion!